Bioinformatics startup BostonGene has launched CLIA-certified and CAP-accredited liquid biopsy, immunoprofiling, and spatial proteomics solutions. These solutions integrate multiple AI-based molecular and immune profiling techniques to analyze a patient's disease, supporting clinical trials and research. The solutions aim to improve patient outcomes and transform precision medicine approaches.

BostonGene's spatial proteomics solution offers a comprehensive overview of tumor cells, immune cell infiltration, and tissue architecture based on cell-to-cell interactions. The immunoprofiling solution identifies surrogate biomarkers for patient selection success, monitors disease progression and treatment response, and guides immunotherapy treatment, while its liquid biopsy assay detects gene alterations for disease progression and treatment response prediction.

Key benefits of using BostonGene's solutions include well-defined and representative clinical trial populations, along with the assessment of treatment safety and effectiveness, monitoring of side effects, and selection of appropriate patient populations for therapies. These solutions provide evidence-based recommendations for personalized treatment selection and generate a personalized roadmap for therapeutic decision-making.